reduction 26 weeks greater reduction plaque patients 3 mg 10 mg doses tested 54 weeks data 6 mg arm not available 54 weeks group started later fourth group patients received 1 mg dose not helped drug trial measures test cognition questionnaire 30 point scale test mental acuity 18 point clinical dementia rating scale tests loss ability function test placebo patients worsened 3.14 points year versus significantly smaller declines patients receiving aducanumab 3 mg 10 mg 0.75 0.58 points respectively second scale placebo group worsened 2.04 points year scores better drug groups 10 mg dose reached statistical significance decline 0.59 points